tradingkey.logo
tradingkey.logo
検索

Evolus Inc

EOLS
ウォッチリストに追加
6.900USD
+0.160+2.37%
終値 07/02, 13:00ET15分遅れの株価
454.29M時価総額
損失額直近12ヶ月PER

詳細情報 Evolus Inc 企業名

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Incの企業情報

企業コードEOLS
会社名Evolus Inc
上場日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)
従業員数332
証券種類Ordinary Share
決算期末Feb 08
本社所在地520 Newport Center Dr Ste 1200
都市NEWPORT BEACH
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92660-7022
電話番号19492844555
ウェブサイトhttps://www.evolus.com/
企業コードEOLS
上場日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)

Evolus Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

よくある質問

Evolus Incの上位5名の株主は誰ですか?

Evolus Incの上位5名の株主は以下のとおりです。Mr. Vikram Malik

Evolus Inc(EOLS)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Evolus Incの株式を保有している機関は391社あり、保有株式の総市場価値は約50.03Mで、全体の75.98%を占めています。2025Q4と比較して、機関の持ち株は-16021350.00増加しています。